Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients

PURPOSE: This study aimed to investigate the biomarkers of sintilimab (anti–PD-1) plus IBI305 (a bevacizumab biosimilar) in advanced hepatocellular carcinoma (HCC), as well as their safety and efficacy. PATIENTS AND METHODS: A total of 50 patients with advanced HCC received sintilimab (200 mg) plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wen, Gong, Caifeng, Peng, Xuenan, Bi, Xinyu, Sun, Yongkun, Zhou, Jianguo, Wu, Fan, Zeng, Huiying, Wang, Yan, Zhou, Hui, Zhao, Hong, Cai, Jianqiang, Zhou, Aiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662860/
https://www.ncbi.nlm.nih.gov/pubmed/35275208
http://dx.doi.org/10.1158/1078-0432.CCR-21-3972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662860/
https://www.ncbi.nlm.nih.gov/pubmed/35275208
http://dx.doi.org/10.1158/1078-0432.CCR-21-3972

Ejemplares similares